The item has been added to your shopping cart.
Home » Anumana and Novartis Ink Software Development Deal
Anumana and Novartis Ink Software Development Deal
Mayo Clinical spinoff Anumana has entered into a multi-year collaboration with Novartis to develop artificial intelligence (AI)-powered software tools to detect cardiovascular conditions from electrocardiograms (ECGs).
The companies aim to develop a digital point-of-care tool that can be used to optimize medical therapies to reduce the risk of potentially avoidable hospitalizations and cardiovascular death.
The collaboration will support Anumana’s efforts to implement AI-enabled diagnostic software that can detect signals from ECGs that humans cannot interpret, the companies said.
The financial terms of the deal were not disclosed.
Upcoming Events
-
18Jul
-
21Oct